An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
Public ClinicalTrials.gov record NCT00738582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Study identification
- NCT ID
- NCT00738582
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Morphotek
- Industry
- Enrollment
- 89 participants
Conditions and interventions
Conditions
Interventions
- Cisplatin Drug
- MORAb-009 (Amatuximab) Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 30, 2008
- Primary completion
- Jun 29, 2011
- Completion
- Jan 9, 2014
- Last update posted
- Sep 21, 2022
2008 – 2014
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama, Birmingham | Birmingham | Alabama | 35294 | — |
| University of California, San Diego | La Jolla | California | 92093 | — |
| UCLA Medical Hematology & Oncology | Los Angeles | California | 90095 | — |
| University of California, San Francisco | San Francisco | California | 94115 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Christiana Care Health System | Newark | Delaware | 19713 | — |
| Emory University School of Medicine | Atlanta | Georgia | 30322 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Johns Hopkins University--Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| NIH/National Cancer Institute | Bethesda | Maryland | 20892 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00738582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2022 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00738582 live on ClinicalTrials.gov.